Did you know that almost 40% of Alpha-1 Research Registry participants report symptoms of liver disease like fatty liver or NASH? While most symptoms of Alpha-1 Antitrypsin Deficiency (Alpha-1) are lung-related, many may not realize that Alpha-1 is a problem that begins in your liver, with the buildup of an abnormal protein causing liver fibrosis and scarring. This eventually leads to chronic liver disease in many patients. Those with chronic liver disease in their family understand the difficult journey for Alpha-1 Liver Disease, as there is yet to be a cure.
With the newest advancements in medicine, progress is underway to help find a potential treatment for this condition. In the rare disease community, it is often clinical trials that find new treatments for the future. If you have been diagnosed with Alpha-1 Associated Liver Disease, there may be hope on the horizon.
The Redwood Clinical Study for Liver-Affected Alphas Continues Enrollment!
The Takeda-sponsored Redwood Study for Alpha-1 Liver Disease is still enrolling and needs volunteers like you! The investigational study drug, TAK-999 (fazirsiran), aims to reduce the production of the abnormal Z-AAT protein and its buildup in the liver. The reduction in levels of the protein may result in a decrease in liver scarring. The investigational study drug is being evaluated alongside the placebo, which appears similar to TAK-999 but contains no active medication. The study is designed to help researchers understand whether TAK-999 can reduce liver scarring caused by Alpha-1 Liver Disease.
Who Can Participate in the Redwood Study?
- Individuals between 18 and 75 years of age
- Have confirmed or suspected diagnosis of the PiZZ genotype for Alpha-1 Liver Disease or have a family member with a confirmed or suspected diagnosis.
- Individuals who do not have a history of the following: liver cancer or any organ transplant
- Individuals who have not smoked any substance for the past 6 months
Study Details:
- Participation in The Redwood Study will last approximately 4.5 years.
- Eligible participants will be chosen at random to receive either TAK-999 (fazirsiran) or a placebo.
- The procedures performed during the study (at no cost to participants) include liver biopsies, questionnaires, physical examinations, vital sign measurements, pulmonary function tests, and blood sample collections.
How do I enroll?
The first step is to complete the following pre-screening form to see if you may qualify. Please note this is not a full list of criteria and additional screening may be needed. Please click the link below to begin.
To access the Alpha-1 Foundation Pre-Screening, click here.
For any questions or concerns, please contact the Alpha-1 Foundation Research Registry Coordinators at 1-877-228-7321 ext. 245 or 252, or alpha1registry@alpha1.org.
